Boston Scientific
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $5,138,000 | $5,442,000 | $5,203,000 | $5,286,000 |
Gross Profit | 3,428,000 | 3,848,000 | 3,613,000 | 3,937,000 |
EBITDA | 979,000 | 1,511,000 | 1,603,000 | 1,155,000 |
EBIT | 1,156,000 | 1,252,000 | 790,000 | |
Net Income | 578,000 | 907,000 | 1,337,000 | 668,000 |
Net Change In Cash | 5,138,000 | 5,442,000 | 5,203,000 | 5,286,000 |
Free Cash Flow | 868,000 | 1,279,000 | 171,000 | 1,013,000 |
Cash | 609,000 | 539,000 | 1,524,000 | 2,045,000 |
Basic Shares | 1,452,000 | 1,484,900 | 1,495,000 | 1,495,800 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $20,074,000 | $16,747,000 | $14,240,000 | $12,682,000 |
Gross Profit | 13,853,000 | 10,267,000 | 8,831,000 | 7,714,000 |
EBITDA | 5,102,000 | 3,938,000 | 3,453,000 | 2,741,000 |
EBIT | 3,734,000 | 2,669,000 | 2,257,000 | 1,605,000 |
Net Income | 2,886,000 | 1,854,000 | 1,593,000 | 698,000 |
Net Change In Cash | 20,074,000 | 16,747,000 | 14,240,000 | 12,682,000 |
Cost of Revenue | -1,033,000 | |||
Free Cash Flow | 3,658,000 | 2,645,000 | 1,703,000 | 914,000 |
Cash | 2,045,000 | 414,000 | 865,000 | 928,000 |
Basic Shares | 1,494,500 | 1,485,900 | 1,463,500 | 1,439,700 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | $0.73 |
2026-06-30 | $0.86 |
2026-03-31 | $0.80 |
2025-12-31 | $0.80 |